Encouraging results from our phase-I trial (NADPARK)! Oral nicotinamide riboside holds promise as a neuroprotective therapy for Parkinson’s disease.
The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease
Researchers from Haukeland University Hospital conducted a phase I trial of NAD-replenishment
therapy with oral nicotinamide riboside (NR) in Parkinson’s disease (PD). NR increased
cerebral NAD levels, and this was associated with altered brain metabolism and clinical
improvement. The findings nomin…
therapy with oral nicotinamide riboside (NR) in Parkinson’s disease (PD). NR increased
cerebral NAD levels, and this was associated with altered brain metabolism and clinical
improvement. The findings nomin…